Key result
DJ-1 promotes neuroprotection in cerebral ischemia by stabilizing mitochondrial function and boosting antioxidant defenses.
Why the study?
Does DJ-1 (PARK7) activation provide neuroprotection and limit brain injury in ischemic stroke?
Does DJ-1 (PARK7) activation provide neuroprotection and limit brain injury in ischemic stroke?
DJ-1 (PARK7) emerges as a promising redox-responsive therapeutic target for neuroprotection in ischemic stroke.
Ischemic stroke remains a leading cause of global mortality and long-term disability, driven largely by oxidative stress, mitochondrial dysfunction, and inflammatory cascades. DJ-1 (PARK7), a redox-sensitive protein originally implicated in Parkinson's disease, has emerged as a critical neuroprotective regulator in cerebral ischemia. Oxidation of its cysteine-106 residue enables DJ-1 to stabilize mitochondrial function, suppress reactive oxygen species, and activate Nrf2-dependent antioxidant defenses. DJ-1 deficiency markedly exacerbates infarct size and neuronal vulnerability, whereas its activation confers robust neuroprotection. This review highlights DJ-1 as a promising redox-responsive therapeutic target for limiting ischemic brain injury.
No takes yet. Share an insight, caveat, or question.
Ganamurali et al. (2026) conducted a review in Ischemic stroke. DJ-1 (PARK7) was evaluated. DJ-1 (PARK7) acts as a critical neuroprotective regulator in cerebral ischemia by stabilizing mitochondrial function and activating antioxidant defenses, representing a promising therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: